

1 **Point-of-care lung ultrasonography for early identification of mild COVID-19: a**
2 **prospective cohort of outpatients in a Swiss screening center**

3

4 Siméon SCHAAD^{1*†}, Thomas BRAHIER^{1*}, Mary-Anne HARTLEY^{2,3}, Jean-Baptiste
5 CORDONNIER³, Luca BOSSO⁵, Tanguy ESPEJO⁵, Olivier PANTET⁴, Olivier HUGLI⁵,
6 Pierre-Nicolas CARRON⁵, Jean-Yves MEUWLY^{6*}, Noémie BOILLAT-BLANCO^{1*}

7

8 *Equal contribution to this work

9 †Corresponding author

10

11 ¹ Infectious Diseases Service, University Hospital of Lausanne, Switzerland; ² Digital global
12 Health Department, Center for primary care and public health, University of Lausanne,
13 Switzerland; ³ Machine Learning and Optimization Laboratory, EPFL, Switzerland; ⁴ Intensive
14 Care Unit, University Hospital of Lausanne, Switzerland; ⁵ Emergency Department, University
15 Hospital of Lausanne, Switzerland; ⁶ Department of Radiology, University Hospital of
16 Lausanne, Switzerland.

17

18 **Running title:** LUS for diagnosis of mild COVID-19

19

20 **Contact information:** Siméon Schaad, Service of Infectious Diseases, University Hospital of
21 Lausanne (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland, Phone: +41 79 524 15
22 85, E-mail: simeon.schaad@unil.ch

23

24 **Conflicts of interest:** none declared

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Funding and support:** this work was supported by the Leenards foundation and by Lausanne

27 University Hospital

28

29 **Abstract**

30 **Background**

31 Early identification of SARS-CoV-2 infection is important to guide quarantine and reduce
32 transmission. This study evaluates the diagnostic performance of lung ultrasound (LUS), an
33 affordable, consumable-free point-of-care tool, for COVID-19 screening.

34 **Methods**

35 This prospective observational cohort included adults presenting with cough and/or dyspnea at
36 a SARS-CoV-2 screening center of Lausanne University Hospital between March 31st and May
37 8th, 2020. Investigators recorded standardized LUS images and videos in 10 lung zones per
38 subject. Two blinded independent experts reviewed LUS recording and classified abnormal
39 findings according to pre-specified criteria to investigate their predictive value to diagnose
40 SARS-CoV-2 infection according to PCR on nasopharyngeal swabs (COVID^{pos} vs COVID^{neg}).
41 We finally combined LUS and clinical findings to derive a multivariate logistic regression
42 diagnostic score.

43 **Results**

44 Of 134 included patients, 23% (n=30/134) were COVID^{pos} and 77% (n=103/134) were
45 COVID^{neg}; 85%, (n=114/134) cases were previously healthy healthcare workers presenting
46 within 2 to 5 days of symptom onset (IQR). Abnormal LUS findings were significantly more
47 frequent in COVID^{pos} compared to COVID^{neg} (45% versus 26%, p=0.045) and mostly consisted
48 of focal pathologic B-lines. Combining LUS findings in a multivariate logistic regression score
49 had an area under the receiver-operating curve of 63.9% to detect COVID-19, but improved to
50 84.5% with the addition of clinical features

51 **Conclusions**

52 COVID^{pos} patients are significantly more likely to have lung pathology by LUS. Our findings
53 have potential diagnostic value for COVID-19 at the point of care. Combination of clinical and
54 LUS features showed promising results, which need confirmation in a larger study population.
55

56 **What is already known on the subject**

- 57 • Lung ultrasonography (LUS) is a consumable-free, easy-to-use, portable, non-radiating
58 and non-invasive screening tool that can be performed at the bedside: its diagnostic
59 performance for pneumonia has been established.
- 60 • Recent studies conducted in emergency department showed a correlation between LUS
61 findings and COVID-19 diagnosis.

62 **What the study adds**

- 63 • This is the first study assessing the diagnostic performance of LUS for COVID-19 in
64 outpatients with mild acute respiratory tract infection.
- 65 • Mild COVID-19 patients are more likely to have lung pathology by LUS compared with
66 COVID-19 negative.
- 67 • Combination of clinical and LUS features showed promising results with a potential
68 diagnostic value for COVID-19 at the point of care.

69 **Introduction**

70 A year into the pandemic, Coronavirus Disease (COVID-19) remains a constant threat,
71 overburdening the healthcare system. Current molecular diagnostic tests such as PCR and rapid
72 antigen/antibody tests rely on consumables, which are vulnerable to shortages and saturation
73 during exponential demand. The use of lung imaging as a diagnostic tool for COVID-19 has
74 shown promises. Chest CT has a good sensitivity for patients triaged in emergency departments
75 [1,2] and has even been able to detect pathology in asymptomatic cases, suggesting its potential
76 as an early screening test in specific populations [3–5]. However, CT and even X-rays expose
77 patients to ionizing radiation, are costly, and often not available in decentralized screening sites.
78 Lung ultrasonography (LUS) is an alternative, consumable-free, easy-to-use, portable, non-
79 radiating and non-invasive screening tool that can be performed at the bedside, with simple
80 disinfection between patients and only a negligible cost of ultrasound gel as a consumable. It

81 would allow immediate identification of infected patients at the point-of-care and be invaluable
82 to the sustainable control of the pandemic. Its diagnostic performance for pneumonia has been
83 established using chest CT as a gold standard [6]. For COVID-19, recent studies conducted in
84 emergency departments showed several LUS patterns ranging from mild interstitial infiltrate,
85 to lung consolidation, which correlated with disease progression and outcome [7,8]. However,
86 these studies included mostly severe patients in emergency departments or intensive care units,
87 which may lead to overoptimistic diagnostic performance of LUS due to a spectrum effect [9].
88 To our knowledge, no studies have described LUS findings in subjects with mild COVID-19.
89 This study aims to compare LUS characteristics between SARS-CoV-2 PCR-confirmed
90 (COVID^{pos}) and PCR-negative (COVID^{neg}) patients in a screening center and explore LUS
91 performance for identification of COVID-19 outpatients.

92 **Methods**

93 ***Study design, setting and population***

94 This prospective cohort study recruited consecutive outpatients at the COVID-19 screening
95 center in Lausanne University Hospital, Switzerland (CHUV) between March 31st and May 8th
96 2020. All adults (age \geq 18 years) presenting at the center with cough and/or dyspnea and who
97 fulfilled eligibility criteria for nasopharyngeal SARS-CoV-2 real time (Rt-) PCR according to
98 the State recommendations at the time of the study were eligible. These State criteria were the
99 presence of symptoms suggestive of COVID in a health worker or a subject with at least one
100 vulnerability criterion, *i.e.* age \geq 65 years old or having at least one comorbidity (obesity,
101 diabetes, active cancer, chronic cardiovascular, pulmonary, liver, renal or inflammatory
102 disease). Exclusion criteria were uninterpretable Rt-PCR results or absence of LUS recording.
103 Written informed consent was obtained from all participants.

104 To ensure that LUS abnormal findings would be specific of a respiratory tract infection, we
105 included a control group of healthy volunteers, matched for age (\pm 5 years), sex, and smoking
106 status with COVID^{pos} patients (Supplementary Table 1). These volunteers were asymptomatic
107 during the previous 15 days (absence of odynophagia, cough, dyspnea, runny nose, fever, loss
108 of smell or taste) and did not have a documented SARS-CoV-2 infection.

109 At inclusion, demographics, comorbidities, symptoms (including duration), and vital signs were
110 collected using a standardized electronic case report form in REDCap® (Research Electronic
111 Data Capture). Patients were subsequently classified as either COVID^{pos} or COVID^{neg}
112 according to the SARS-CoV-2 RT-PCR results (at inclusion or at any time during the 30-day
113 follow-up if the test was repeated for the same clinical episode). We assessed 30-day outcome
114 by phone using a standardized interview (persistence of symptoms, secondary medical
115 consultation, hospital admission, death).

116

117 The study was approved by the Swiss Ethics Committee of the canton of Vaud (CER-VD 2019-
118 02283).

119 *Patient and public involvement*

120 Subjects were not involved in the design or conduct of this study.

121 *Sample size*

122 The minimum sample size required for this study was 100 patients with a clinical suspicion of
123 COVID. It was calculated using a COVID prevalence of 20% and an estimated sensitivity of
124 LUS to identify COVID^{pos} at 80% This sample size guarantees a power of 80% with a false
125 discovery rate of 5% [10].

126 *Lung ultrasonography*

127 Three medical students trained in LUS performed image acquisitions in the triage site. The first
128 10 acquisitions were done under direct supervision of an experienced board-certified expert
129 (OP) who verified the quality of recorded images. Acquisition was standardized according to
130 the “10-zone method” [11,12], consisting of five zones per hemithorax. Two images (sagittal
131 and transverse) and 5 second videos were systematically recorded in every zone with a Butterfly
132 IQTM personal US system (Butterfly, Guilford, CT, USA), using the lung preset. The LUS probe
133 and the electronic tablet were disinfected with an alcohol-based solution between each patient
134 to avoid nosocomial spread [13].

135 For interpretation of LUS pathology, a physician experienced in LUS (TB) and an expert
136 radiologist (JYM), blinded to patients’ diagnoses, independently filled a standardized report
137 form as previously described [8]. Discordance between the two readers were adjudicated by a
138 third expert (OP). The abnormal images were summed up in a LUS score for each patient, as
139 previously described [8,14,15].

140 *Statistical analyses*

141 Differences between COVID^{pos} and COVID^{neg} patients for all collected demographic and
142 clinical features as well as LUS findings and LUS score were evaluated by Mann Whitney or
143 chi-squared test, as appropriate. A bilateral p value <0.05 was considered as indicative of
144 statistical significance. A multivariate logistic regression was built from 22, 15, 10 and 8
145 features using recursive feature elimination (RFE), originally including the following:

146 **1) LUS findings (n=10)**

- 147 • Number of pathological zones for each of the five patterns (normal, pathological B lines,
148 confluent B lines, pleural thickening, consolidation) (n=5)
- 149 • A dichotomized variable for the presence/absence of the above four pathological
150 patterns detected (n=4)
- 151 • Binary variables for the presence of multifocal disease (n=1)

152 **2) Symptoms at presentation (n=8)**

- 153 • Binary variables for the presence of cough, sputum, dyspnea, fever, anosmia,
154 rhinorrhea, myalgia, and diarrhea

155 **3) Vital signs (n=3)**

- 156 • Continuous variables for temperature, oxygen saturation, and respiratory rate

157 **4) Epidemiological history (n=1)**

- 158 • Binary variable for a history of known unprotected contact with a COVID-19 case

159 Feature coefficients are presented, as well as their importance in ranked order from RFE .

160 Performance at several stages of the RFE are reported, using the top 22, 15, 10 and 8 features.

161 Models using just LUS or just clinical findings were also built.

162 Diagnostic performance is reported as sensitivity, specificity, positive and negative predictive
163 values (PPV, NPV), positive and negative likelihood ratios (LR+, LR-) and area under the
164 receiver-operator curve (AUC). Due to the dataset size, we report findings on the entire dataset.

165 A diagnostic score was derived from the summed coefficients, normalized within a range from

166 -6 (COVID^{pos} highly unlikely) to +4 (COVID^{pos} highly likely) and the number of patients in
167 each class are presented for each value of the score. The optimal cut-point was chosen using
168 Youden index [16].

169 The kappa coefficient was calculated to measure the inter-rater agreement between the two LUS
170 readers. R Core Team (2019) statistical software and python 3.0 with the sklearn library was
171 used for analyses. Similar analyses were attempted on the outcome at 30-day follow up but
172 impossible due to the limited sample size.

173 The reporting of our results followed the STARD guidelines.

174 **Results**

175 ***Demographics and clinical presentation***

176 A total of 141 patients met inclusion criteria and were enrolled into the study; eight (5%) were
177 later excluded, due to uninterpretable PCR results or LUS technical issues. Of the 134
178 remaining patients, 31 (23%) were classified as COVID^{pos} and 103 (77%) as COVID^{neg} based
179 on Rt-PCR test. Among the 13 COVID^{neg} patients who had a second screening test during the
180 30-day follow-up, only one had a positive SARS-CoV-2 Rt-PCR, related to a clearly distinct
181 clinical episode. This patient was thus classified as COVID^{neg}. Most patients were female
182 (63%), healthcare workers (85%) with a median age of 35 years; most sought out testing within
183 the first 5 days of symptom onset (Table 1). COVID^{pos} patients had fewer comorbidities than
184 COVID^{neg}, the latter suffering mostly from asthma, obesity or hypertension. COVID^{pos} patients
185 presented more often with a history of fever and anosmia, but less often with dyspnea than
186 COVID^{neg} patients. Vital signs at inclusion were normal in most patients of both groups.

187 ***Lung ultrasonography findings***

188 Lung ultrasound was abnormal in 31% of patients (Table 2). The two observers showed good
189 concordance to differentiate a normal from an abnormal LUS, with a kappa of 0.67. Most
190 anomalies were focal and unilateral. The most frequent patterns were pathologic B-lines and
191 thickening of the pleura with pleural line irregularities. Only 9.1% of control subjects presented
192 any abnormal finding on LUS, and all these anomalies were focal pathologic or confluent B
193 lines (Supplementary Table 2).

194 Among all symptomatic patients, two factors were significantly associated with abnormal LUS:
195 SARS-CoV-2 infection and history of fever (Table 3). Indeed, COVID^{pos} patients had abnormal
196 LUS findings significantly more frequently compared with COVID^{neg} (45% versus 26%,
197 $p=0.045$). However, this feature alone was poorly sensitive (45%) and specific (74%). No

198 specific ultrasonographic pattern on its own significantly distinguished COVID^{pos} from
199 COVID^{neg} subjects (Table 2).

200 Although not statistically different, the proportion of COVID-19^{pos} with abnormal LUS
201 findings was positively associated with symptoms duration. While only 30% of COVID-19^{pos}
202 patients had abnormal LUS within 2 days of symptom onset, 52% of patients had pathological
203 LUS after 2 days (p=0.24).

204 *Multivariate diagnostic score.*

205 We combined LUS findings with symptoms, vital signs and a binary feature for known contact
206 with a COVID-19 case to build a multivariate logistic regression diagnostic score. Using all
207 features, the score had 78.8% sensitivity, 84.0% specificity, 83.1% PPV, 61.4% NPV, 4.9 LR+,
208 0.3 LR- and 84.5% AUC (Figure 1). We present a plot on which to assess the score according
209 to a desired sensitivity/specificity trade-off.

210 In Table 4, score performance with several combinations of features at various stages of RFE
211 are presented. The strongest positive predictor was any evidence of pleural thickening at any
212 number of sites (coefficient: +0.69) with LUS, although it became a negative predictor with an
213 increasing number of sites with this feature (-0.40). The presence of pathological B lines and
214 confluent pathological B lines were also positively associated with COVID infection in this
215 score. All three of the above patterns were retained by RFE within the top seven features. The
216 LUS features that were negative and quickly eliminated by RFE were those describing
217 consolidation and multifocal pathology. Cough, fever and anosmia were the highest ranked
218 symptoms (coefficient ≥ 0.4), in line with previous reports. While LUS patterns were highly
219 ranked in the RFE, rerunning the model without LUS findings reduced AUC by only 4% (AUC
220 84.5% vs 80.3%). LUS findings were poorly sensitive in the absence of clinical features (AUC:
221 63.9% Sensitivity: 45.5%, Specificity: 77.3%, PPV: 66.7%, NPV: 55.6%, LR+: 2.0, LR-: 0.7).

222 Combining all 22 features and using RFE, we observe that removing 7 features had minimal
223 impact on score performance, and removing 12 features reduces AUC by only 4% compared to
224 the original.

225 ***30-day outcome***

226 The 30-day follow-up was available for 121/134 (90%) patients. None was hospitalized or died
227 during follow-up. COVID^{pos} patients had more frequently persistent symptoms (fatigue,
228 dyspnea or anosmia) at 30-day compared with COVID^{neg} (Table 1).

229 The presence of an abnormal LUS at inclusion was not associated with symptom persistence
230 (Table 3).

231 As no patients were admitted or died, we could not analyze the value of LUS findings to predict
232 critical clinical outcome.

233 **Discussion**

234 Lung pathology is detectable by chest CT early in the course of COVID disease, even in
235 asymptomatic patients, suggesting that lung imaging might have a place as a complementary
236 diagnostic tool [3]. However, large scale CT screening is not feasible even in hospital settings
237 with abundant resources. Point-of-care LUS is now affordable, portable and implementable in
238 a decentralized setting and has all the attributes to become a pragmatic community-based
239 screening tool.

240 We evaluated the diagnostic performance of LUS in a prospective cohort of subjects with mild
241 acute respiratory tract infection attending a COVID-19 Swiss screening center. COVID^{pos}
242 outpatients more frequently had abnormal LUS findings at inclusion compared with COVID^{neg}.
243 However, LUS findings alone had insufficient sensitivity, NPV and LR- to recommend LUS as
244 an independent screening tool in outpatients. The combination of LUS findings with clinical
245 presentation showed promising results.

246 The limited sensitivity of LUS in our population is discordant with previous studies, which
247 showed a good sensitivity (89-97%) to identify Rt-PCR-confirmed COVID-19. These
248 retrospective studies were conducted in emergency departments and included patients with
249 severe and critical COVID-19 infection[17–19]. Other studies using chest CT also showed an
250 excellent sensitivity (97-98%) to diagnose COVID-19 [2,20,21]. However, all these studies
251 were conducted in hospitalized patients with severe or critical disease, preventing extrapolation
252 to our milder population screened for symptoms only.

253 The clinical severity of the disease strongly affects the performance of diagnostic tests, and
254 particularly the sensitivity of LUS. We conclude that while LUS may be an interesting COVID-
255 19 screening tool in emergency departments, it is not reliable when used alone in patients with
256 mild disease. In the only study investigating chest CT features in patients with asymptomatic
257 (73%) or mild (27%) COVID-19, which was conducted in the passengers of the cruise ship

258 *Diamond Princess*, 54% of asymptomatic patients and 79% of patients with mild disease
259 presented opacities on chest CT. These results suggested the potential use of chest CT in clinical
260 decision making [3]. Most opacities were located in the peripheral areas of the lung, where LUS
261 is performant. Patients included in the *Diamond Princess* study were older compared with our
262 study population (mean of 63 ± 15 years vs. 39 ± 13 years), a possible explanation for the lower
263 proportion of patients with lung involvement in our study. However, our data suggest that a
264 combination of LUS findings and clinical characteristics might achieve better detection of mild
265 COVID-19 in young outpatients.

266 We observed more abnormal LUS findings in COVID^{pos} patients who had more than 2 days of
267 symptoms (52% versus 30%), although our results were not statistically significant. Concordant
268 with our findings, a relationship between the duration of infection and the proportion of
269 abnormal radiological findings has been described [22–24]. In one study, only 44% of patients
270 presenting within 2 days of symptoms had an abnormal CT, while this proportion rose to 91%
271 after 3 to 5 days and 96% after 5 days [24]. This study did not provide any data on COVID-19
272 severity. In another study using chest X-ray in patients admitted to the emergency department,
273 the proportion of an abnormal chest X ray increased with the duration of symptoms (63% in the
274 first 2 days to 84% after 9 days) [25].

275 In our study, most patients with abnormal LUS findings presented with focal pathologic B lines,
276 confluent B lines or pleural thickening, irrespective of the etiology of the acute respiratory tract
277 infection. Inclusion of healthy volunteers confirmed the causality between LUS findings and
278 acute respiratory tract infections. Indeed, only 9% of healthy volunteers presented LUS
279 anomalies (and all were focal pathologic B lines).

280 Two previous study showed that thickened pleural lines on LUS were significantly associated
281 with COVID-19 [17,18]. However, in a third report, LUS findings were similar in both COVID-
282 19 and non-COVID-19 patients [19].

283 **Limitations**

284 Our study has some limitations. First, most of our subjects were healthy and young healthcare
285 workers, which prevents extrapolation of our results to an older and comorbid population.
286 However, young, healthy subjects are of a prime importance in the management of the virus
287 spread [26]. Second, SARS-CoV-2 Rt-PCR nasopharyngeal swab was used as the gold
288 standard, and we might have missed some early infections when it has limited sensitivity [27].
289 However, it is considered as the reference diagnostic method. Furthermore, we sought to
290 mitigate technical and sample collection error using validated nucleic acid amplification tests
291 and a dedicated trained medical team performing nasopharyngeal swabs [28]. In addition, we
292 had 30-day follow-up, which may have reduced the number of patients misclassified as
293 COVID^{neg}. To better investigate the predictive potential of LUS findings, we built a
294 multivariate score. The small sample size and high feature count (n= 22) exposes the model to
295 the risk of overfitting. Thus, this score is not ready for clinical use, but rather is a mean to
296 demonstrate the feature importance by RFE.

297 **Conclusion**

298 To our knowledge, this is the first study, which assessed the use of LUS in a screening center
299 outpatient population with mild COVID-19. As disease severity plays an important role in the
300 ultrasonographic findings, LUS is poorly sensitive as a SARS-CoV-2 screening tool in the
301 context of mild community-level screening. However, the good performance of a combination
302 of clinical and LUS features showed promising results, which could be used to avoid a PCR
303 test in patients with a negative screening. These results need confirmation in a larger study
304 population.

305 **Declarations**

306 **Funding**

307 This work was supported by an academic award of the Leenaards Foundation (to NBB), by the
308 Foundation of Lausanne University Hospital, and the Emergency Department Lausanne
309 University Hospital. The funding bodies had no role in the design of the study and collection,
310 analysis and interpretation of data and in writing the manuscript.

311 **Acknowledgements**

312 We thank all the patients who accepted to participate and make this study possible. We thank
313 all healthcare workers of the triage unit of the emergency department of the University Hospital
314 of Lausanne, who supported the study and managed COVID-19 suspected patients.

315 **Authors' contributions**

316 JYM, OH, PC, NBB: study conception, study design, study performance, study management,
317 data analysis, data interpretation and manuscript writing. SS, TB, JYM, OP: LUS images
318 review, data interpretation and critical review of the manuscript.

319 TE, LB: LUS images recording, data interpretation and critical review of the manuscript.

320 MH, JC: data analysis, interpretation, visualisations and critical review of the manuscript.

321 All authors approved the final version of the manuscript and agreed to be accountable for all
322 aspects of the work in ensuring that questions related to the accuracy or integrity of any part of
323 the work are appropriately investigated and resolved.

324 NBB had full access to all the data in the study and takes responsibility for the integrity of the
325 data and the accuracy of the data analysis.

326

327 References

- 328 1 Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, *et al.* Clinical Characteristics of
329 Coronavirus Disease 2019 in China. *N Engl J Med* 2020;**382**:1708–20.
- 330 2 Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, *et al.* Correlation of Chest CT and RT-
331 PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
332 1014 Cases. *Radiology* 2020;:200642.
- 333 3 Inui S, Fujikawa A, Jitsu M, Kunishima N, Watanabe S, Suzuki Y, *et al.* Chest CT
334 Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus
335 Disease 2019 (COVID-19). *Radiol Cardiothorac Imaging* 2020;**2**:e200110.
- 336 4 Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, *et al.* Radiological findings from 81
337 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*
338 2020;**20**:425–34.
- 339 5 Islam N, Salameh J-P, Leeftang MM, Hoof L, McGrath TA, van der Pol CB, *et al.*
340 Thoracic imaging tests for the diagnosis of COVID-19. *Cochrane Database Syst Rev*
341 2020;**11**:CD013639.
- 342 6 Orso D, Guglielmo N, Copetti R. Lung ultrasound in diagnosing pneumonia in the
343 emergency department: a systematic review and meta-analysis. *Eur J Emerg Med*
344 2018;**25**:312–21.
- 345 7 Peng Q-Y, Wang X-T, Zhang L-N. Findings of lung ultrasonography of novel corona
346 virus pneumonia during the 2019–2020 epidemic. *Intensive Care Med* 2020;:1–2.
- 347 8 Brahier T, Meuwly J-Y, Pantet O, Brochu Vez M-J, Gerhard Donnet H, Hartley M-A,
348 *et al.* Lung ultrasonography for risk stratification in patients with COVID-19: a prospective
349 observational cohort study. *Clin Infect Dis Off Publ Infect Dis Soc Am* Published Online First:
350 17 September 2020. doi:10.1093/cid/ciaa1408
- 351 9 Mulherin SA, Miller WC. Spectrum Bias or Spectrum Effect? Subgroup Variation in
352 Diagnostic Test Evaluation. *Ann Intern Med* 2002;**137**:598.
- 353 10 Bujang MA, Adnan TH. Requirements for Minimum Sample Size for Sensitivity and
354 Specificity Analysis. *J Clin Diagn Res JCDR* 2016;**10**:YE01–6.
- 355 11 Rambhia SH, D’Agostino CA, Noor A, Villani R, Naidich JJ, Pellerito JS. Thoracic
356 Ultrasound: Technique, Applications, and Interpretation. *Curr Probl Diagn Radiol*
357 2017;**46**:305–16.
- 358 12 Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW,
359 *et al.* International evidence-based recommendations for point-of-care lung ultrasound.
360 *Intensive Care Med* 2012;**38**:577–91.
- 361 13 AIUM. Guidelines for Cleaning and Preparing External- and Internal-Use Ultrasound
362 Transducers and Equipment Between Patients as well as Safe Handling and Use of
363 Ultrasound Coupling Gel. 2020.
- 364 14 Mayo PH, Copetti R, Feller-Kopman D, Mathis G, Maury E, Mongodi S, *et al.*
365 Thoracic ultrasonography: a narrative review. *Intensive Care Med* 2019;**45**:1200–11.
- 366 15 Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, *et al.*
367 Proposal for International Standardization of the Use of Lung Ultrasound for Patients With
368 COVID-19. *J Ultrasound Med*;n/a. doi:10.1002/jum.15285
- 369 16 Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its
370 corresponding Youden Index to discriminate individuals using pooled blood samples.
371 *Epidemiol Camb Mass* 2005;**16**:73–81.
- 372 17 Pare JR, Camelo I, Mayo KC, Leo MM, Dugas JN, Nelson KP, *et al.* Point-of-care
373 Lung Ultrasound Is More Sensitive than Chest Radiograph for Evaluation of COVID-19.
374 *West J Emerg Med* 2020;**21**:771–8.
- 375 18 Bar S, Lecourtois A, Diouf M, Goldberg E, Bourbon C, Arnaud E, *et al.* The

- 376 association of lung ultrasound images with COVID-19 infection in an emergency room
377 cohort. *Anaesthesia* 2020;**75**:1620–5.
- 378 19 Sorlini C, Femia M, Nattino G, Bellone P, Gesu E, Francione P, *et al.* The role of lung
379 ultrasound as a frontline diagnostic tool in the era of COVID-19 outbreak. *Intern Emerg Med*
380 Published Online First: 22 October 2020. doi:10.1007/s11739-020-02524-8
- 381 20 Raptis CA, Hammer MM, Short RG, Shah A, Bhalla S, Bierhals AJ, *et al.* Chest CT
382 and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date. *Am J*
383 *Roentgenol* 2020;**215**:839–42.
- 384 21 Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, *et al.* Sensitivity of Chest CT for
385 COVID-19: Comparison to RT-PCR. *Radiology* 2020;**296**:E115–7.
- 386 22 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019
387 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *Am J Roentgenol*
388 2020;**215**:87–93.
- 389 23 Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, *et al.* A rapid advice
390 guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected
391 pneumonia (standard version). *Mil Med Res* 2020;**7**:4.
- 392 24 Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, *et al.* Chest CT Findings
393 in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection.
394 *Radiology* 2020;**295**:200463.
- 395 25 Vancheri SG, Savietto G, Ballati F, Maggi A, Canino C, Bortolotto C, *et al.*
396 Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the
397 onset of symptoms. *Eur Radiol* 2020;**30**:6161–9.
- 398 26 Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, *et al.* Screening of
399 healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-
400 19 transmission. *eLife* 2020;**9**. doi:10.7554/eLife.58728
- 401 27 Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jatton K, *et al.* Diagnostic
402 strategies for SARS-CoV-2 infection and interpretation of microbiological results. *Clin*
403 *Microbiol Infect* 2020;**26**:1178–82.
- 404 28 Opota O, Brouillet R, Greub G, Jatton K. Comparison of SARS-CoV-2 RT-PCR on a
405 high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the
406 diagnostic of COVID-19 on various clinical samples. *Pathog Dis* 2020;**78**:ftaa061.
- 407
- 408

409 **Figure Legend**

410 **Figure 1.** A multivariate logistic regression diagnostic score (x-axis) to discriminate COVID^{pos}
411 from COVID^{neg} patients (black and white bars respectively with count on y axis). Sensitivity
412 (—) and specificity (—) of the score are plotted with Youden's index (sensitivity + specificity
413 -1) marked in orange. All 22 features are used in the depicted image on a model trained on all
414 data points.

415

Tables

Table 1. Demographics, clinical characteristics and 30-day outcome of study participants according to nasopharyngeal Rt-PCR SARS-CoV-2 results

	All (n=134)	SARS-Co-V2 positive (n=31)	SARS-CoV-2 negative (n=103)	P value
Demographics				
Female sex	84 (63)	20 (65)	64 (62)	0.810
Age, years; Mean (SD)	35.5 [29, 46]	34 [26, 42]	37 [29, 50]	0.316
Known contact with COVID subject	33 (28)	10 (34)	23 (25)	0.334
Current smoker	39 (29)	7 (23)	32 (31)	0.362
Alcohol misuse	3 (2.2)	0 (0)	3 (2.9)	0.337
Reason for testing				
Vulnerable person ^a	20 (15)	6 (19)	14 (14)	0.430
Healthcare worker	114 (85)	25 (81)	89 (86)	0.430
Comorbidities				
Any	38 (28)	3 (9.7)	35 (34)	0.008
Hypertension	10 (7.5)	1 (3.2)	9 (8.7)	0.306
Diabetes	2 (1.)	0 (0)	2 (1.9)	0.434
Obesity	16 (12)	5 (16)	11 (11)	0.423
Asthma	17 (13)	1 (3.2)	16 (16)	0.071
Cardiovascular disease ^b	5 (3.7)	1 (3.2)	4 (3.9)	0.865

Pulmonary disease ^c	3 (2.2)	0 (0)	3 (2.9)	0.337
Active cancer	3 (2.2)	2 (6.5)	1 (1.0)	0.071
Hepatitis or liver cirrhosis	2 (1.4)	0 (0)	2 (1.9)	0.434
Chronic renal failure ^d	2 (1.4)	0 (0)	2 (1.9)	0.434
Chronic inflammatory disease	4 (3.0)	0 (0)	4 (3.9)	0.265
Symptoms				
Duration of symptoms, days; Median (IQR)	3 [2, 5]	3 [2, 4]	3 [2, 5]	0.942
Duration of symptoms				
0-2 days	50 (38)	10 (32)	40 (39)	
3-5 days	57 (43)	18 (58)	39 (38)	
≥6 days	26 (20)	3 (9.7)	23 (23)	
Cough	118 (88)	30 (97)	88 (85)	0.088
Expectorations	27 (20)	10 (32)	17 (17)	0.055
Dyspnea	79 (59)	13 (42)	66 (64)	0.028
History of fever	75 (56)	23 (74)	52 (50)	0.020
Anosmia	24 (18)	10 (32)	14 (14)	0.017
Rhinorrhea	76 (57)	20 (65)	56 (54)	0.317
Odynophagia	55 (41)	13 (42)	42 (41)	0.908
Myalgia	91 (68)	25 (81)	66 (64)	0.083
Diarrhea	34 (25)	5 (16)	29 (28)	0.177
Temperature, °C; Median (IQR)	36.9 [36.6, 37.3]	37 [36.7, 37.5]	36.9 [36.6, 37.2]	0.202
Respiratory rate, beaths/minute; Median (IQR)	18 [16, 20]	18 [14, 20]	18 [16, 20]	0.236

Saturation, %; Median (IQR)	97 [97, 98]	98 [97, 98]	97 [97, 98]	0.403
Heart rate, beats/minute; Median (IQR)	86 [77, 95]	87 [79, 90]	86 [76, 98]	0.955
Follow up at 30 days				
Persistence of any symptoms at day 30	28 (23)	12 (41)	16 (17)	0.008
Fatigue	14 (10)	9 (29)	5 (4.9)	0.000
Myalgia	6 (4.5)	3 (9.7)	3 (2.9)	0.110
Cough	10 (7.4)	3 (9.7)	7 (6.8)	0.592
Expectoration	2 (1.4)	1 (3.2)	1 (0.97)	0.364
Dyspnea	9 (6.7)	6 (19)	3 (2.9)	0.001
Fever	2 (1.4)	1 (3.2)	1 (0.97)	0.364
Anosmia	8 (6.0)	7 (23)	1 (0.97)	0.000
Rhinorrhea	1 (0.8)	1 (3.2)	0 (0)	0.067
Odynodysphagia	2 (1.4)	1 (3.2)	1 (0.97)	0.364
Diarrhea	2 (1.4)	1 (3.2)	1 (0.97)	0.364
Medical consultation during follow-up	32 (26)	9 (31)	23 (25)	0.521
Hospitalization / Death	0 (0)	0 (0)	0 (0)	

Data are presented as n (%) unless indicated.

Missing values: contact with infected people, 15; medical consultation at inclusion, 1; vital signs, 5; duration of symptoms, 1; obesity, 1.

Abbreviations: IQR, interquartile range.

^a ≥ 65 years old or comorbidity (obesity, diabetes, active cancer, chronic cardiovascular, pulmonary, liver, renal or inflammatory disease)

^b Arrhythmia, coronary disease.

^c Chronic obstructive pulmonary disease, fibrosis.

^d Stage III–V according to CKD classification.

402 **Table 2.** Lung ultrasound characteristics of study participants according to nasopharyngeal Rt-PCR SARS-CoV-2 results

	All (n=134)	SARS-CoV-2 positive (n=31)	SARS-CoV-2 negative (n=103)	P value
Abnormal lung ultrasound (any abnormal finding)	41 (31)	14 (45)	27 (26)	0.045
Abnormal lung ultrasound, apart from focal B-lines	30 (22)	11 (35)	19 (18)	0.046
Multifocal	16 (12)	6 (19)	10 (9.7)	0.146
Bilateral	8 (6.0)	3 (9.7)	5 (4.9)	0.320
Number of pathologic zones; Median (IQR)	0 [0, 1]	0 [0, 1]	0 [0, 1]	0.044
Pathologic B-lines (≥ 3)	20 (15)	6 (19)	14 (14)	0.430
Confluent B-lines (White lung)	11 (8.2)	4 (13)	7 (6.8)	0.277
Pleural thickening	18 (13)	6 (19)	12 (12)	0.270
Consolidations (> 1 cm)	1 (0.75)	0 (0)	1 (0.97)	0.582
Pleural effusion	1 (.75)	0 (0)	1 (.97)	0.000
LUS score; Median (IQR)	0 [0, 1]	0 [0, 3]	0 [0, 1]	0.044

403

404

405 **Table 3.** Demographics and clinical characteristics of study participants according to the presence of an abnormal lung ultrasound

	All (n=134)	Abnormal LUS (n=41)	Normal LUS (n=93)	P value
Demographics				
Female sex	84 (63)	28 (68)	56 (60)	0.373
Age; Median (IQR)	35.5 [29, 46]	38 [31, 48]	35 [28, 45]	0.574
Current cigarette smoker	39 (29)	12 (29)	27 (29)	0.978
Alcohol misuse	3 (2.2)	0 (0)	3 (3.2)	0.245
Reason of testing				
Vulnerable person	20 (15)	3 (7.3)	17 (18)	0.101
Healthcare worker	114 (85)	38 (93)	76 (82)	0.101
Positive Rt-PCR result	31 (23)	14 (34)	17 (18)	0.045
Comorbidities				
Any	38 (28)	13 (32)	25 (27)	0.568
Hypertension	10 (7.5)	3 (7.3)	7 (7.5)	0.966
Diabetes	2 (1.5)	1 (2.4)	1 (1.1)	0.549
Obesity	16 (12)	3 (7.3)	13 (14)	0.265
Asthma	17 (13)	7 (17)	10 (11)	0.311
Cardiovascular disease ^b	5 (3.7)	2 (4.9)	3 (3.2)	0.642
Pulmonary disease ^c	3 (2.2)	0 (0)	3 (3.2)	0.245
Active cancer	3 (2.2)	1 (2.4)	2 (2.2)	0.917
Hepatitis or liver cirrhosis	2 (1.5)	1 (2.4)	1 (1.1)	0.549
Chronic renal failure ^d	2 (1.5)	0 (0)	2 (2.2)	0.344

Chronic inflammatory disease	4 (3.0)	0 (0)	4 (4.3)	0.178
Symptoms				
Duration of symptoms, days; Median (IQR)	3 [2, 5]	3 [2, 5]	3 [2, 5]	0.344
Duration of symptoms				0.210
0-2 days	50 (38)	11 (22)	39 (78)	
3-5 days	57 (43)	21 (37)	36 (63)	
≥ 6 days	26 (20)	9 (35)	17 (65)	
Cough	118 (88)	34 (83)	84 (90)	0.224
Expectorations	27 (20)	7 (17)	20 (22)	0.556
Dyspnea	79 (59)	25 (61)	54 (58)	0.752
Hemoptysis	2 (1.5)	0 (0)	2 (2.2)	0.344
History of fever	75 (56)	29 (71)	46 (49)	0.022
Anosmia	24 (18)	11 (27)	13 (14)	0.074
Rhinorrhea	76 (57)	21 (51)	55 (59)	0.394
Odynophagia	55 (41)	17 (41)	38 (41)	0.948
Myalgia	91 (68)	31 (76)	60 (65)	0.205
Diarrhea	34 (25)	8 (20)	26 (28)	0.301
Temperature, °C; Median (IQR)	36.9 [36.6, 37.3]	37 [36.6, 37.5]	36.9 [36.6, 37.2]	0.270
Respiratory rate, beaths/minute; Median (IQR)	18 [16, 20]	18 [16, 20]	18 [16, 20]	0.330
Saturation, %; Median (IQR)	97 [97, 98]	97 [97, 98]	97 [97, 98]	0.385
Heart rate, beats/minute; Median (IQR)	86 [77, 95]	88 [79, 98]	85 [76.5, 94]	0.170
Follow-up at 30 days				

Persistence of any symptoms at day 30	28 (23)	9 (24)	19 (23)	0.924
Fatigue	14 (10)	7 (17)	7 (7.5)	0.096
Myalgia	6 (4.5)	2 (4.9)	4 (4.3)	0.882
Cough	10 (7.5)	3 (7.3)	7 (7.5)	0.966
Expectorations	2 (1.5)	0 (0)	2 (2.2)	0.344
Dyspnea	9 (6.7)	4 (9.8)	5 (5.4)	0.351
Fever	2 (1.5)	0 (0)	2 (2.2)	0.344
Anosmia	8 (6.0)	1 (2.4)	7 (7.5)	0.252
Rhinorrhea	1 (.75)	0 (0)	1 (1.1)	0.505
Odynophagia	2 (1.5)	1 (2.4)	1 (1.1)	0.549
Diarrhea	2 (1.5)	0 (0)	2 (2.2)	0.344
Medical consultation during follow-up	26 (21)	10 (26)	16 (19)	0.364
Hospitalization/Death	0 (0)	0 (0)	0 (0)	

406 Data are presented as n (%) unless otherwise indicated.
407 Abbreviations: IQR, interquartile range.
408 ^a ≥ 65 years old or comorbidity (obesity, diabetes, active cancer, chronic cardiovascular, pulmonary, liver, renal or inflammatory disease)
409 ^b Arrhythmia, coronary disease.
410 ^c Chronic obstructive pulmonary disease, fibrosis.
411 ^d Stage III–V according to CKD classification

412

413 **Table 4.** Multivariate logistic regression for COVID diagnosis

RFE selection order	Feature groups				Coefficient*		Diagnostic performance with various feature sets:			
	LUS findings (n=10)	Symptoms (n=8)	Vital signs (n=3)	Epidemiological history (n=1)	Neg	Pos	22-0 features=22 10 LUS 8 symptoms 1 contact 3 signs	22-7 features=15 6 LUS 8 symptoms 1 contact <u>NO</u> signs	22-12 features=10 5 LUS 4 symptoms 1 contact <u>NO</u> signs	22-14 features=8 5 LUS 3 symptoms <u>NO</u> contact <u>NO</u> signs
1 (removed last)		Cough				0.40	Sens: 78.8%	Sens: 75.8%	Sens: 84.8%	Sens: 81.8%
2	Pleural thickening (any)					0.69	Spec: 84.0%	Spec:83.2%	Spec: 72.3%	Spec: 62.2%
3	Pleural thickening (number of sites)				-0.40		AUC: 84.5%	AUC: 83.5%	AUC: 80.2%	AUC: 76.6%
4		Fever				0.44	LR+: 4.9	LR+: 4.5	LR+: 3.1	LR+: 2.2
5	Confluent B lines (number of sites)					0.41	LR-: 0.3	LR-: 0.3	LR-: 0.2	LR-: 0.3
6	Normal pattern (number of sites)					0.29	PPV: 83.1%	PPV: 81.8%	PPV: 75.4%	PPV: 68.4%
7	Pathologic B lines (number of sites)					0.49	NPV: 61.4%	NPV: 80.6%	NPV: 73.5%	NPV: 64.7%
8		Anosmia				0.43				
9				Contact with COVID-19		0.47				
10		Dyspnea			-0.28					
11		Myalgia				0.37				
12		Diarrhea			-0.49					
13	Multifocality				-0.26					
14		Rhinorrhea				0.35				
15		Sputum				0.41				
16			Oxygen saturation			0.20				
17	Consolidation (any)				-0.18					
18			Temperature (°C)			0.22				

LUS findings only	Clinical only
Sens: 45.5%	Sens: 72.7%
Spec: 77.3%	Spec: 79.8%
AUC: 63.9%	AUC: 80.3%

19			Respiratory rate		-0.30	
20	Consolidation (any)				-0.18	
21	Pathologic B lines (any)				-0.07	
22 <i>(removed first)</i>	Confluent B lines (any)				0.26	

LR+: 2.0	LR+: 3.6
LR-: 0.7	LR-: 0.3
PPV: 66.7%	PPV: 78.3%
NPV: 55.6%	NPV: 64.5%

414

415

416

417


418

419

Multivariate logistic regression for COVID diagnosis where selection order is indirectly proportional to the feature's predictive importance, in recursive feature elimination (RFE), i.e., the feature labeled 22 was removed first, while 1 was retained until the end. Four feature groups containing 10 LUS findings, 8 symptoms, 3 vital signs and 1 epidemiological history of contact are color-coded according to their coefficient in the multivariate score including all 22 features (orange positive correlation with COVID and blue negative correlation). *The coefficient in multivariate scores is susceptible to multicollinearity.

420 **Figures**

421 **Figure 1**



422

423

424 **List of Supplemental Digital Content**

425 SupplementaryTables.docx